• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

ingsoo.tiong@unimelb.edu.au

Credentials


Position
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
Education
Masters (Research)
Monash University
Bachelors Degree
University of Otago

Dr Ing-Soo Tiong

Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology

67 Scholarly works
1 Projects

HIGHLIGHTS

  • 2026

    Journal article

    2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
    DOI: 10.1182/blood.2025031480
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
  • 2023

    Journal article

    Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
    DOI: 10.1182/blood.2022016090
  • 2022

    Journal article

    Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
    DOI: 10.1182/bloodadvances.2022008325
  • 2020

    Journal article

    Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined with Modified Intensive Chemotherapy
    DOI: 10.1200/JCO.20.00572
  • 2020

    Journal article

    Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
    DOI: 10.1182/BLOOD.2019003988
  • 2019

    Journal article

    Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
    DOI: 10.1038/s41375-018-0261-3
Ing-Soo Tiong

Latest Honours,
Awards and Fellowships


2017
Fellow of the Royal Australasian College of Physicians (FRACP)
2017
Fellow of the Royal College of Pathologists of Australasia ( FRCPA)

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets
    DOI: 10.1038/s41375-026-02886-6
  • 2026

    Journal article

    Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
    DOI: 10.1182/bloodadvances.2025017083
  • 2026

    Journal article

    Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange program
    DOI: 10.1016/j.pathol.2025.09.003
  • 2026

    Journal article

    The telomeric puzzle inTP53-mutant myeloid neoplasms
    DOI: 10.1182/blood.2025031124
  • 2025

    Journal article

    Genomic variation in DDX41 identified through clinical sequencing
    DOI: 10.1111/bjh.70086
  • 2025

    Journal article

    Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer
    DOI: 10.1182/bloodadvances.2025016063
  • 2025

    Journal article

    Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
    DOI: 10.1182/bloodadvances.2024014900
  • 2025

    Journal article

    CAR T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
    DOI: 10.1056/NEJMoa2309728

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224